Evolving Science of PAH Treatment

Slides:



Advertisements
Similar presentations
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
Advertisements

Copyright © 2011 Actelion Pharmaceuticals Ltd SERAPHIN: RESULTS FROM A LANDMARK STUDY.
Upfront Combination Therapy vs Step-Up Approach for PAH:
HOPE: Heart Outcomes Prevention Evaluation study
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Exploring Early Combination Therapy in PAH
Monitoring and Modifying Treatment in PAH
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
A Paradigm Shift in PAH.
An Update on Oral Prostanoids: Advancing Care for PAH?
Cardiogenic Shock.
UNDERSTANDING RISK STRATIFICATION IN PAH:
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
The Latest Data on Oral Prostacyclin Therapy in PAH
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
Select Topics in Cardiovascular Medicine
Treatment of Complicated Intra-abdominal Infections
All About PAH:.
What Would You Do in This Case of MDD?
T2DM and CV Outcomes Trials: A Deep Dive!
PAH Therapy Revisited.
PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence
An Update on PCSK9 Inhibitors
Improving Risk Assessment and Early Diagnosis in PAH
Updates in Pulmonary Arterial Hypertension
Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy
What's New in Dyslipidemia?
Treatment of HR+ Breast Cancer: A Clinical Update
WHO Clinical Classification of PH Complex Cases in PH.
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Risk Assessment in PAH.
Gene Therapy: Past, Present, and Future
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Examining the Latest Evidence in PAH
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Macitentan in Pulmonary Hypertension Due To Left Ventricular Dysfunction: MELODY-1 Jean-Luc Vachièry, Marion Delcroix, Hikmet Al-Hiti, Michela Efficace,
Navigating Treatment Options in PAH
Preventing Clinical Events in PAH
PAH and Prostacyclin Pathways in Focus
When Is Intrathecal Drug Delivery Appropriate?
PAH-Related Morbidity as a Predictor of Mortality
PAH Treatment.
Pulmonary Arterial Hypertension and Connective Tissue Disease
What's New in PAH?.
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
Iron Deficiency in Heart Failure
Pulmonary Hypertension Updates From 2018
Incorporating Prostacyclins Into Practice
EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Optimal Treatment of PAH
An Update on PCSK9 Inhibitors
When Is Intrathecal Drug Delivery Appropriate?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
Addressing Cardiovascular Events:
Incorporating New PAH Treatments Into Clinical Practice
PAH Pathways: What Do the Data Tell Us?”
Clinical Comparisons in CTEPH
Pulmonary Arterial Hypertension and Hospitalizations
My PAH Patient.
The Power of As-Treated Analyses
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Evolving Science of PAH Treatment

Program Goals

Paradigm Shift in PAH Treatment

Earlier PAH Clinical Trials

6-Minute Walk Test

Meta-Analysis of 22 RCTs

Changes in PAH Trials Over Time

Spectrum of PAH Double-Blind RCTs to Date Study Durations and Sizes

PAH Clinical Trials Evaluating Morbidity and Mortality Endpoints

Clinical Efficacy/Safety SERAPHIN Trial[a,b]

Clinical Efficacy/Safety GRIPHON Trial

GRIPHON: Primary Composite Endpoint

SERAPHIN Placebo vs Macitentan 3 mg vs Macitentan 10 mg (1:1:1)

Treatment Algorithm for PAH

Rationale for Combination Therapy

Expert Consensus Recommendations for Combination Therapy Have Improved With Increasing Experience

An Evolving Paradigm From Sequential to Initial Up-Front Combination Therapy

Case Study 29-Year-Old Woman, Referred for Abnormal Echocardiogram May 2015

Case Study (cont)

Case Study (cont)

Treatment Goals

Case Study (cont) Plan

Case Study (cont)

Case Study Intensification of Therapy?

Conclusion

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)